Completed PHASE2 INTERVENTIONAL 2-arm NCT02147067

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA) (MARINA)

Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis

Sponsor: Emory University

Updated 8 times since 2017 Last updated: May 17, 2019 Started: Sep 30, 2014 Primary completion: Mar 31, 2018 Completion: Jun 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Microvascular Angina and is currently completed. Emory University leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2019 — Jan 2021 [monthly]

Completed PHASE2
Aug 2018 — Jun 2019 [monthly]

Completed PHASE2

Status: Recruiting → Completed · Phase: PHASE4 → PHASE2

▶ Show 3 earlier versions

Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE4
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE4

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Emory University
Gilead Sciences

Data source: Emory University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States